How did Sunoco's revenue and expenses shift in Q4 2024?

Sunoco's revenue and expenses in Q4 2024 showed a significant shift, with the company's net income being driven by a substantial increase in revenue, particularly in the Plasma-Derived Therapies and Immunology business segments. Here's a detailed analysis: 1. **Revenue by Business**: Sunoco's revenue was primarily driven by its Plasma-Derived Therapies and Immunology business, which generated $271.4 billion in revenue. This was a significant contributor to the overall revenue of the company. 2. **Cost of Sales**: The Cost of Goods Sold (COGS) for Sunoco in Q4 2024 was $2.69 billion. This represents the direct costs associated with the production and sale of the company's goods and services. 3. **General and Administrative Expenses**: Sunoco's General and Administrative (G&A) expenses were $2.41 billion in Q4 2024. These expenses include overhead costs, administrative salaries, and other expenses related to running the business. 4. **Net Income**: Despite the high expenses, Sunoco was able to achieve a net income of $2.69 billion in Q4 2024. This indicates that the company was able to generate sufficient revenue to cover its expenses and earn a profit. In conclusion, Sunoco's revenue and expenses in Q4 2024 were characterized by a strong revenue growth, particularly in the Plasma-Derived Therapies and Immunology business, which was able to cover the company's expenses and result in a positive net income.